Entheon Biomedical Corp. (CSE:ENBI.X)
Canada · Delayed Price · Currency is CAD 0.0600
0.00 (0.00%)
At close: Sep 2, 2026
Entheon Biomedical Income Statement
Financials in millions CAD. Fiscal year is December - November.
Millions CAD. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
| - | - | - | 0.25 | 0.19 | - | |
Revenue Growth | - | - | - | 31.97% | - | - |
Gross Profit | - | - | - | 0.25 | 0.19 | - |
Selling, General & Admin | 0.32 | 0.33 | 0.33 | 0.56 | 2.5 | 4.45 |
Research & Development | - | - | - | - | 1.2 | 1.21 |
Operating Expenses | 0.32 | 0.33 | 0.33 | 0.56 | 3.79 | 8.21 |
Operating Income | -0.32 | -0.33 | -0.33 | -0.31 | -3.6 | -8.21 |
Interest & Investment Income | 0.01 | 0.01 | 0.02 | 0.01 | 0 | 0.01 |
Currency Exchange Gain (Loss) | -0 | -0 | -0 | -0 | 0.02 | 0 |
Other Non Operating Income (Expenses) | 0.01 | - | - | 0 | 0.25 | -0 |
EBT Excluding Unusual Items | -0.31 | -0.32 | -0.32 | -0.3 | -3.33 | -8.2 |
Gain (Loss) on Sale of Investments | - | - | - | 0 | -0.07 | 0.21 |
Gain (Loss) on Sale of Assets | - | - | - | - | 1.34 | - |
Other Unusual Items | 0.35 | - | - | - | - | - |
Pretax Income | 0.04 | -0.32 | -0.32 | -0.3 | -2.06 | -8 |
Earnings From Continuing Operations | 0.04 | -0.32 | -0.32 | -0.3 | -2.06 | -8 |
Earnings From Discontinued Operations | - | - | - | - | -6.46 | -0.89 |
Net Income | 0.04 | -0.32 | -0.32 | -0.3 | -8.52 | -8.89 |
Net Income to Common | 0.04 | -0.32 | -0.32 | -0.3 | -8.52 | -8.89 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 14 | 13 | 8 | 6 | 6 | 5 |
Shares Outstanding (Diluted) | 14 | 13 | 8 | 6 | 6 | 5 |
Shares Change | 27.09% | 73.25% | 30.96% | - | 8.85% | 97.83% |
EPS (Basic) | 0.00 | -0.02 | -0.04 | -0.05 | -1.44 | -1.64 |
EPS (Diluted) | 0.00 | -0.02 | -0.04 | -0.05 | -1.44 | -1.64 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Free Cash Flow | -0.09 | -0.31 | -0.36 | -0.36 | -1.95 | -5.33 |
Free Cash Flow Per Share | -0.01 | -0.02 | -0.05 | -0.06 | -0.33 | -0.98 |
Gross Margin | - | - | - | 100.00% | 100.00% | - |
Operating Margin | - | - | - | -124.96% | -1898.18% | - |
Profit Margin | - | - | - | -119.85% | -4492.23% | - |
Free Cash Flow Margin | - | - | - | -143.79% | -1030.49% | - |
EBITDA | - | - | - | - | -3.6 | -8.18 |
D&A For EBITDA | - | - | - | - | 0 | 0.04 |
EBIT | -0.32 | -0.33 | -0.33 | -0.31 | -3.6 | -8.21 |
EBIT Margin | - | - | - | -124.96% | - | - |
Revenue as Reported | - | - | - | 0.25 | 0.19 | - |